kidney cancer | pharmaphorum

Skip to main content

Tuesday 9 June 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

kidney cancer

News

bavencio-sup-®-sup-avelumab-1-HR

Pfizer/Merck KGaA eye fast review for kidney cancer combo

A combination therapy based around Pfizer and Merck KGaA’s Bavencio has outperformed standard of care in a late-stage trial in untreated but advanced kidney cancer.

News

Cancer-cells-16-9

Fotivda approved in Scotland for kidney cancer

The Scottish Medicines Consortium (SMC) has recommended regular NHS funding for EUSA Pharma's kidney cancer drug Fotivda, enabling around 165 patients a year to access the treatment.

News

Known as Cabometyx in the US, the drug is licensed by Ipsen from Exelixis

Ipsen takes on BMS as kidney cancer pill launches in EU

Cabometyx could take market share from Opdivo

News

US regulator approves new use for Pfizer's Sutent

US regulator approves new use for Pfizer's Sutent

FDA granted new kidney cancer indication despite advisers' split decision

News

FDA advisers split on new kidney cancer use for Pfizer's Sutent

FDA advisers split on new kidney cancer use for Pfizer's Sut...

Committee could not decide if Sutent can be used after the removal of a cancerous kidney.

News

lee_morley

EUSA Pharma's Fotivda approved in EU for kidney cancer

UK pharma gets licence for second cancer drug

Load more results

Editor's Picks

Servier wagers $2.65bn on Edgewise muscular dystrophy drug

ASCO26: AZ triplet makes waves in frontline liver cancer

ASCO26: Big win for Erleada in perioperative prostate cancer

Lilly licenses Hanmi GLP-2 drug in $1.26bn deal

First human trial backs AI-designed 'universal' vaccine

News

ADA: AZ reveals oral GLP-1 data in obesity, diabetes

ADA: AZ reveals oral GLP-1 data in obesity, diabetes

AstraZeneca prepares to move its oral GLP-1 elecoglipron into phase 3 for obesity and diabetes, after reporting encouraging phase 2b data at ADA.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company